Updated:
Moberg Pharma AB
Moberg Pharma AB is a Swedish public pharma firm developing topical treatments for nail fungus, led by MOB-015. It licenses products globally.
Moberg Pharma AB
Moberg Pharma AB is a publicly listed Swedish pharmaceutical company (Nasdaq Stockholm: MOB) focused on dermatology and topical therapeutics. Its origins trace to the early 2000s, when it began developing terbinafine-based nail fungus treatments; today it holds a portfolio of patented and proprietary formulations for skin and nail conditions. The firm's core asset is MOB-015, a high-concentration terbinafine nail lacquer for onychomycosis, which has completed Phase 3 trials in Europe and the US. Moberg also commercializes over-the-counter products like Kerasal and Dermik. Rather than building its own salesforce, the company licenses its products to regional partners. Known partners include Menarini for Europe and Sato Pharmaceutical for Japan. As a publicly traded entity, Moberg Pharma reports financials quarterly. Its most recent operational shift was the acquisition of Onset Therapeutics in 2022, which brought in complementary topical assets. The firm employs a small core team in Stockholm and leans on contract manufacturing and licensing to scale. Moberg Pharma's structural differentiator is its hybrid model: it operates as a development-stage biotech with partnered commercialization, rather than a fully integrated pharma. This keeps capital deployment lean while allowing it to monetize assets through royalties and upfront licensing payments.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Stockholm, Sweden
Sector focus
Frequently asked questions
Who makes investment decisions at Moberg Pharma AB?
As a publicly traded company, executive decisions are made by the CEO and board of directors. The firm does not disclose a named CIO or dedicated investment team beyond its executive management, which is typical for a development-stage pharma company.
How does Moberg Pharma source its product pipeline?
Moberg Pharma sources its pipeline primarily through internal R&D and selective acquisitions. Its lead candidate MOB-015 was developed in-house; the 2022 acquisition of Onset Therapeutics brought in additional topical assets. The firm also in-licenses technology when it aligns with its focus on dermatology.
Is Moberg Pharma structured as a family office or a publicly traded company?
Moberg Pharma AB is a publicly traded limited company on Nasdaq Stockholm. It does not operate as a family office. Its shareholding is dispersed, with no single family having disclosed majority control.
Does Moberg Pharma participate in fund commitments or direct deals?
Moberg Pharma operates as an operating company, not an investment firm. It does not make fund commitments or direct institutional investments. Its capital allocation is focused on R&D, licensing, and occasional bolt-on acquisitions.
What investment stages does Moberg Pharma typically target?
Moberg Pharma targets late-stage clinical development through to commercial-stage assets. Its lead candidate MOB-015 has completed Phase 3 trials. The firm also markets already-approved OTC products like Kerasal.
Which sectors does Moberg Pharma explicitly avoid?
Moberg Pharma focuses strictly on dermatology and topical therapeutics. It does not pursue systemic drugs, oncology, vaccines, or medical devices.
Where does Moberg Pharma's underlying wealth come from?
Moberg Pharma is a publicly traded company with no disclosed family wealth origin. It is capitalized through equity offerings, revenues from product sales, and licensing fees rather than by a single family or individual.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: